Rivaroxaban Market: Size, Growth, Regional Analysis, And Market Analysis
Rivaroxaban: In some countries, Rivaroxaban, also known as Xarelto, is an oral anticoagulant developed and manufactured by Bayer. Janssen Pharmaceutical markets it in the United States. It's the most widely available direct factor Xa inhibitor taken orally. Rivaroxaban is absorbed quickly in the gut, with the highest factor Xa inhibition occurring four hours after a dose. The effects persist for about 8–12 hours, although factor Xa movement does not return to normal within 24 hours. Therefore a once-daily dose is possible. In addition, because an anticoagulant drug is being developed to prevent and treat embolism and non-hemorrhagic stroke, the rivaroxaban market is likely to rise in the next few years due to the rising prevalence of these medical disorders. Market Analysis: The global Rivaroxaban market is valued at 6908.7 million USD in 2020 is expected to reach 12070 million USD by the end of 2026, growing at a CAGR of 8.2% during 2021-2026. Expanding clinical preliminaries for